双重Axl/MerTK抑制剂INCB081776构建促炎肿瘤免疫微环境并增强抗PDL1疗效于头颈癌
该研究探讨Axl和MerTK在头颈癌免疫「冷」微环境中的作用,使用小分子抑制剂INCB081776同时靶向两者。结果显示靶向Axl和MerTK可减少M2并诱导M1巨噬细胞极化;体内单用或联合抗PDL1似乎减慢小鼠口腔癌生长、增加促炎免疫浸润并减少抗炎免疫浸润。结论认为在小鼠头颈癌模型中同时靶向Axl和MerTK可减慢肿瘤生长并形成促炎肿瘤免疫微环境。
要点
- 靶向Axl和MerTK可减少M2并诱导M1巨噬细胞极化。
- 体内INCB081776单用或联合抗PDL1似乎减慢小鼠口腔癌生长。
- INCB081776增加促炎免疫浸润并减少抗炎免疫浸润。
核心结论
- 数据表明,在小鼠头颈癌模型中,使用INCB081776同时靶向Axl和MerTK(单用或联合抗PDL1)可减慢肿瘤生长并形成促炎肿瘤免疫微环境。
研究设计与样本
- 研究评估Axl和MerTK在形成免疫「冷」肿瘤免疫微环境中的作用,使用Axl和MerTK小分子抑制剂INCB081776同时靶向两者。
- 评估INCB081776和/或抗PDL1对小鼠口腔癌(MOC)细胞生长及肿瘤免疫微环境的影响。
主要发现
- 靶向Axl和MerTK可减少M2并诱导M1巨噬细胞极化。
- 体内INCB081776单用或联合抗PDL1似乎减慢MOC肿瘤生长,增加促炎免疫浸润,并减少抗炎免疫浸润。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tyrosine kinase receptors Axl and MerTK are highly overexpressed in head and neck cancer (HNC) cells, where they are critical drivers of survival, proliferation, metastasis, and therapeutic resistance. METHODS: We investigated the role of Axl and MerTK in creating an immunologically "cold" tumor immune microenvironment (TIME) by targeting both receptors simultaneously with a small molecule inhibitor of Axl and MerTK (INCB081776). Effects of INCB081776 and/or anti-PDL1 on mouse oral cancer (MOC) cell growth and on the TIME were evaluated. RESULTS: Targeting Axl and MerTK can reduce M2 and induce M1 macrophage polarization. In vivo, INCB081776 treatment alone or with anti-PDL1 appears to slow MOC tumor growth, increase proinflammatory immune infiltration, and decrease anti-inflammatory immune infiltration. CONCLUSIONS: This data indicates that simultaneous targeting of Axl and MerTK with INCB081776, either alone or in combination with anti-PDL1, slows tumor growth and creates a proinflammatory TIME in mouse models of HNC.
引用
- Kostecki KL, Iida M, Wiley AL, et al. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head Neck. 2023. PMID: 36939040. doi:10.1002/hed.27340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。